Medical Device Approval: 510(K), Pma, and Regulatory Pathways

FDA classifies medical devices as Class I, II, or III based on risk level. Class I devices present minimal risk and are subject to general controls, including registration and Good Manufacturing Practice (GMP). Class II devices present moderate risk and typically require 510(k) clearance before marketing. Class III devices present the highest risk and require Premarket Approval (PMA) unless they are grandfathered predicate devices. The classification of a device is not always obvious. Devices on the margin between classes require careful analysis before any regulatory strategy is developed.

Defective medical devices counsel analyzes the device classification under the applicable FDA product code, evaluates the regulatory history of similar devices in the FDA predicate database, and advises on the classification determination before any pre-submission strategy is developed.

Software as a Medical Device (SaMD) is subject to FDA jurisdiction when it meets the FD&C Act device definition. Software that diagnoses, treats, or monitors a medical condition is a device. Software that provides general wellness features is not. FDA's Digital Health Center of Excellence coordinates the regulation of SaMD, mobile medical applications, and AI-enabled devices using a risk-tiered approach. Software posing serious risks to patients generally requires 510(k) clearance or PMA.

 Cybersecurity requirements apply to connected devices and require manufacturers to address vulnerabilities in their design controls and post-market monitoring systems.

Digital health laws counsel evaluates whether a digital health product meets the FD&C Act definition of a device, identifies the applicable regulatory pathway, and advises on FDA's cybersecurity guidance requirements for connected and AI-enabled medical devices.

A 510(k) submission demonstrates substantial equivalence to a legally marketed predicate device. Substantial equivalence requires the same intended use as the predicate and characteristics that do not raise new questions of safety and effectiveness. The 510(k) must include a device description, performance testing data, labeling, and a biocompatibility evaluation when applicable. FDA has 90 days to make a substantial equivalence determination after accepting the submission. A 510(k) that receives a Not Substantially Equivalent (NSE) determination is denied clearance. The company may then seek reclassification through the De Novo pathway.

FDA regulatory counsel prepares the 510(k) submission, selects the predicate device that best supports the substantial equivalence argument, manages the FDA additional information request process, and advises on the response strategy when FDA issues a Not Substantially Equivalent determination.

Premarket Approval (PMA) is the most rigorous FDA regulatory submission pathway. It applies to Class III devices without a legally marketed predicate and requires valid scientific evidence, typically from well-controlled clinical investigations, demonstrating safety and effectiveness. PMA approval is conditioned on the manufacturer's ongoing compliance with the conditions of approval, including any post-approval studies required by FDA. The De Novo pathway is available for novel Class I or Class II devices that lack a predicate and are not appropriate for PMA. FDA reviews the De Novo request and may grant it while simultaneously establishing a new device classification that serves as the predicate for future 510(k) submissions.

Healthcare regulations counsel prepares the PMA application, manages the FDA panel advisory meeting process for devices reviewed by an expert committee, and advises on the De Novo request when the device is novel but does not require clinical data at the level PMA demands.

An IDE is required for significant risk devices, meaning those that pose a serious risk to subject safety. IDE studies must be reviewed by an Institutional Review Board (IRB) and include informed consent procedures. FDA reviews the IDE application within 30 days and may approve it, disapprove it, or place it on clinical hold. Non-significant risk device studies require IRB approval but not FDA IDE approval.

Clinical trial litigation counsel prepares the IDE application, advises on the IRB submission and approval process, manages adverse event reporting during the clinical investigation, and advises on the transition from IDE study to PMA submission.

The Pre-Submission (Pre-Sub) program allows manufacturers to consult FDA before filing a 510(k), De Novo, PMA, or IDE. A Pre-Sub is not a requirement. It is a strategic tool. FDA provides written responses within 70 days of the meeting request. Pre-Sub meetings cover the planned predicate selection and substantial equivalence strategy, the proposed clinical study design, and the performance testing protocols FDA will expect in the submission. Manufacturers who skip the Pre-Sub process run a higher risk of receiving additional information requests or denial letters that could have been avoided.

Import and trade compliance counsel manages the Pre-Sub meeting request and preparation, develops the written questions for FDA feedback, and advises on the regulatory submission strategy based on the FDA response and the competitive landscape.

Manufacturers must comply with the Quality System Regulation (QSR) at 21 CFR Part 820. Medical Device Reports (MDRs) must be submitted to FDA within 30 days when a device may have caused a serious injury. The QSR governs design controls, purchasing controls, production controls, corrective and preventive actions, and records. FDA conducts routine and surveillance manufacturing inspections. FDA clearance marks the start of post-market compliance obligations for the life of the device.

Healthcare compliance counsel evaluates the manufacturer's QSR compliance program, prepares responses to FDA inspection observations, and advises on the MDR reporting obligations and post-market surveillance study requirements that apply to cleared or approved devices.

FDA may issue recalls, warning letters, and import alerts, or seek injunctions against manufacturers who violate the FD&C Act. Class I recalls cover devices with a reasonable probability of causing serious adverse health consequences or death. A warning letter requires a written response within 15 business days. The manufacturer must address each FDA observation and provide a corrective action plan. A regulatory submission under FDA review while the manufacturer receives a warning letter for manufacturing violations can be placed on hold until the violations are resolved.

Pharmaceutical regulatory compliance counsel responds to FDA warning letters, manages voluntary and mandatory recall communications, advises on consent decree negotiations, and manages the FDA regulatory submission strategy during active enforcement proceedings.